Lymphocyte transformation during dinitrochlorobenzene contact sensitization. An in vitro and in vivo evaluation of the primary immune response in man.
An evaluation of cell-mediated immunity in man is described that combines the advantages of an in vitro technique, lymphocyte transformation, with the use of contact sensitization to a primary immunogen, dinitrochlorobenzene (DNCB). DNCB, when coupled to autologous or allogeneic peripheral blood leukocytes, forms a complex, DNCB-antigen, that induces lymphocyte transformation specifically in leukocyte cultures from subjects sensitized to DNCB. Sequential studies of lymphocyte transformation to DNCB-antigen show that specifically reactive lymphocytes are first detected at about 10 days after in vivo application of a sensitizing dose of DNCB and reach a peak at about 14-21 days.
D000328:Adult; D000941:Antigens; D002280:Basal Cell Carcinoma / Q000276:immunology; D002478:Cells, Cultured; D004247:DNA / Q000096:biosynthesis; D006801:Humans; D007111:Immunity, Cellular; D007167:Immunotherapy; D066298:In Vitro Techniques; D007962:Leukocytes / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D008213:Lymphocyte Activation; D009578:Nitrobenzenes; D012882:Skin Tests; D013936:Thymidine / Q000378:metabolism; D013997:Time Factors; D014316:Tritium
D000941:Antigens; D009578:Nitrobenzenes; D014316:Tritium; D004247:DNA; D013936:Thymidine